Breaking News, Collaborations & Alliances

Regeneron, Tessera Therapeutics Partner to Develop & Commercialize TSRA-196

TSRA-196 is designed to precisely correct the genetic mutation underlying alpha-1 antitrypsin deficiency (AATD).

Author Image

By: Charlie Sternberg

Associate Editor

Regeneron Pharmaceuticals Inc. and Tessera Therapeutics Inc. have announced a global collaboration to develop and commercialize TSRA-196, Tessera’s lead investigational in vivo Gene Writing program for the treatment of alpha-1 antitrypsin deficiency (AATD), an inherited monogenic disease that can affect the lungs, liver, or both organs. TSRA-196 is designed to precisely correct the genetic mutation underlying AATD, with the goal of restoring production of functional alpha-1 antitrypsin (AAT) ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters